Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neurofibromatosis Type 1

Official title

Evaluation of Percutaneous Cryotherapy in the Treatment of Plexiform Neurofibromas and Unresectable Neurofibromas in Neurofibromatosis Type 1 (NF1)

Overview

Neurofibromatosis type 1 (NF1) is an autosomal dominant disease affecting chromosome 17. It is manifested by a neurogenic tumor proliferation that forms cutaneous, subcutaneous or deep neurofibromas. Neurofibromas can cause functional discomfort, neurogenic pain that is difficult to treat, and severe cosmetic disorders. Treatment is essentially surgical. It is sometimes a heavy invasive surgery with complicated postoperative follow-up and significant scarring on the aesthetic level. Currently, no systemic treatment has proven its effectiveness in this pathology. Percutaneous cryotherapy is a cold thermoablation procedure using fine 17 G needles introduced into the lesion after targeting by imaging. This technique is used in the treatment of soft tissue tumors and desmoid tumors. The treatment of neurofibromas with percutaneous cryotherapy is not well known. Encouraging results (unpublished) have been observed in patients with NF1 treated with cryotherapy at the Léon Bérard Center. The beneficial effect was observed in terms of quality of life (in particular, pain) as well as a decrease in tumor size. On the basis of this first experience, it appears important to corroborate these preliminary results by a prospective study allowing the use of this technique to treat patients with unresectable or resectable neurofibromas but with mutilating surgery in a NF1 context.

Interventions

• Device Cryotherapy
  The cryotherapy treatment lasts approximately 30 minutes during which two 10-minute freezing cycles are performed, separated by a reheating phase. During the freezing phases, the temperature is lowered below -40°C in the ablation zone, a temperature that is lethal for the cells.

Primary outcome measures

• To evaluate the impact of percutaneous cryotherapy on physical health-related quality of life (in patients with inoperable (or operable with mutilating surgery) neurofibroma. [Time frame: 12 months after cryotherapy]

Secondary outcome measures (9)

• To assess each quality of life dimension of the Short Form-36 (SF-36) questionnaire; [Time frame: At baseline, at Month1 post cryotherapy ; Month 3 post cryotherapy; Month 6 post cryotherapy, Month 9 post cryotherapy, Month 12 post cryotherapy, Month 18 post cryotherapy and Month 24 post post cryotherapy ;]
• To evaluate the tumor response [Time frame: Month 3, Month 6, Month 9, Month 12, Month 18 , and Month 24 after cryotherapy]
• To evaluate the functional discomfort [Time frame: At baseline, Month 1; Month 3; Month 6, Month 9, Month12, Month18 and Month 24 post cryotherapy]
• To evaluate the patients' pain [Time frame: At baseline, Month 1; Month 3; Month 6, Month 9, Month 12, Month 18 and Month 24 post cryotherapy]
• To evaluate the safety of percutaneous cryotherapy [Time frame: From cryotherapy to 24 months after cryotherapy]
• To evaluate patients' satisfaction [Time frame: At Month 12 post-cryotherapy;]
• To evaluate patients self-esteem [Time frame: at baseline, Month 1; Month 3; Month 6, Month 9, Month12, Month 18 and Month 24 post-cryotherapy]
• To evaluate the need for multiple percutaneous cryotherapy procedures in case of incomplete response on the target lesion; [Time frame: From cryotherapy to 24 months after cryotherapy]
• To evaluate operating room occupancy time. [Time frame: At Day 0]

Eligibility criteria

Inclusion criteria

• Age ≥18 years;
• Patient with neurofibromatosis type 1 according to NIH criteria ;
• Patient with a benign neurofibromatous lesion that is painful and/or generates functional discomfort and is unresectable or with unacceptable scarring ;
• Neutrophils > 1 G/l in the 14 days prior to inclusion;
• Adequate coagulation test with normals values (as judged by the investigator);
• Signed and dated informed consent document indicating that the patient has been informed of all aspects of the trial prior to enrolment
• Covered by a medical insurance;

Exclusion criteria

• Patient treated with concomitant chemotherapy and/or targeted therapies ;
• Any contraindication to a percutaneous cryotherapy procedure, including the need for ice formation within 1 cm of the spinal cord, brain or other critical nerve structures, bowel or bladder (unless active or passive thermal protective maneuvers are performed);
• Patient with malignant neurofibroma or MPNST ; CT scan without abnormality and if tumor presents a max SUV T/F>1.5 ratio, targeted biopsy is required to confirm benign or malignant histology.
• Patient with neurofibroma in areas at risk for neurological sequelae;
• Patient with cold urticaria with history of angioedema;
• Any cognitive impairment or condition that may limit the use of numerical scales and quality of life questionnaires;
• Patient for whom follow-up does not seem feasible even in the short term;
• Participation in another clinical trial that may interfere with the evaluation of the primary endpoint;
• Patient under tutorshio, curatorship or deprived of liberty;
• Pregnant or breast-feeding woman;
• Any contraindication to the performance of an MRI
• Patient with dysplastic neurofibroma

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation

N/A

Model

Single group

Masking

Open label

Primary purpose

Treatment

Study locations

France · 1 center

• Centre Leon Berard — Lyon

Identifiers

NCT: NCT05199376 · ET21-198

Primary sources (government registries)

• ClinicalTrials.gov (US NIH)

View this study on ClinicalTrials.gov ↗